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Objective: To present the results of a strategy designed to reduce 
the incidence of skin complications in newborns with hypoxic–
ischemic encephalopathy treated with moderate whole-body 
hypothermia. Design: Retrospective study. Setting: Neonatal 
Intensive Care Unit (NICU). Patients: Thirty-nine neonates cooled 
in the considered period. Intervention: Starting from January 
2008, for neonates treated with moderate whole-body hypo-
thermia (33.5 °C), the cooling system was set in “automatic 
servo-controlled mode (ACM)”, where the temperature of the 
circulating water could vary between 4 °C and 42 °C. Starting 
from January 2009, cooling blankets were used in another 
type of automatic mode, the “gradient variable mode (GVM)”, 
where the circulating water was maintained at a specific pre-set 
gradient towards the patient’s body temperature, and a specific 
nursing protocol (NP) was adopted. Measurements and main 
results: Two of the eleven newborns treated with the “ACM” 
exhibited skin complications compatible with subcutaneous fat 
necrosis (SFN). None of the twenty-eight newborns treated with 
the “GVM” exhibited skin complications. A comparison of the 
biochemical and hematological data between these two groups 
revealed that newborns treated after the adopting of a NP and 
the “GVM” showed lower serum protein C and calcium levels, 
and higher platelet levels. Conclusions: Our data suggest that 
newborns undergoing therapeutic cooling may benefit from 
a specific NP and correct cooling unit setting. Should further 
studies confirm our data, this nursing approach could be easily 
adopted.
Keywords:  asphyxia, hypothermia, hypoxic-ischemic 
encephalopathy, newborn, subcutaneous fat necrosis
Introduction
Perinatal hypoxic–ischemic encephalopathy is still the single most 
important cause of serious brain injury in newborns. Recent trials 
have demonstrated that moderate hypothermia (MH) (rectal or 
esophageal temperature 33–34 °C) in asphyxiated neonates, if 
started within 6 h after birth and protracted for 72 h, can signifi-
cantly improve survival and reduce brain injury at 18 months [1]. 
Therefore, therapeutic hypothermia has recently been included in 
the Guidelines of International Consensus on Cardiopulmonary 
Resuscitation and Emergency Cardiovascular Care Science [2].
Cooling needs to be initiated as soon as possible after asphyxia 
[3]. MH can be started passively (by stopping the heating) or by 
applying ice bags to the head and body before and during transfer 
of the neonate to the referring hospital, where active MH can be 
obtained with selective head or whole-body cooling [3].
MH is generally well-tolerated. Side effects, represented by 
sinus bradycardia and thrombocytopenia, are transient and 
reversible with rewarming [4]. Early studies suggested an increase 
in hypotension requiring inotrope infusion in newborns treated 
with hypothermia [4], but a subsequent analysis demonstrated 
that MH does not affect arterial blood pressure [5]. Moreover, 
several cases of subcutaneous fat necrosis (SFN) and cold pannic-
ulitis in newborns undergoing MH have recently been described 
[6–12]. A recent survey reported a prevalence of ~1% among 
infants subjected to MH [13].
In this study, we report the onset of skin complications in two 
asphyxiated newborns treated with whole-body hypothermia, 
and illustrate the results of our strategy to reduce their incidence 
using a nursing protocol (NP) and a specific surface-cooling 
system adjustment. We analyzed the hypothesis that frequent 
mobilization of infants and the limiting of abrupt temperature 
changes of the water circulating in the mattresses might reduce 
the incidence of SFN and the inflammation markers.
Materials and methods
Patients
Starting from January 2008, asphyxiated newborns with 
gestational age ≥36 weeks and birth weight ≥1,800 g admitted to 
the 16-bed Neonatal Intensive Care Unit (NICU) of the A. Meyer 
University Children’s Hospital were treated with moderate whole-
body hypothermia when the following criteria were ascertained: 
(i) metabolic criteria: Apgar score ≤5 at 10 min, or persisting 
need for resuscitation, including endotracheal intubation or mask 
ventilation for more than 10 min after birth, or acidosis (pH 
≤7.0 and/or base deficit ≥−16 mmol/l in umbilical cord blood 
or arterial, venous, or capillary blood) within 60 min after birth; 
(ii) neurological criteria: moderate to severe encephalopathy 
Original article
 Strategies for reducing the incidence of skin complications in  
newborns treated with whole-body hypothermia
luca Filippi1, Serena catarzi1, letizia Padrini1, Patrizio Fiorini1, giancarlo la Marca2, renzo guerrini3 &  
gian Paolo Donzelli4
1Neonatal Intensive Care Unit, Medical Surgical Feto-Neonatal Department, “A. Meyer” University Children’s Hospital, Florence, Italy, 
2Department of Pharmacology, University of Florence, Meyer Children’s Hospital, Florence, Italy, 3Department of Neurology and 
Neurosurgery, “A. Meyer” University Children’s Hospital, Florence, Italy, and 4Department of Sciences for Woman and Child’s Health, 
University of Florence, Meyer Children’s Hospital, Florence, Italy
Correspondence: Luca Filippi, Neonatal Intensive Care Unit – Department of Critical Care Medicine – “A. Meyer” University Children’s Hospital, Viale 
Pieraccini, 24 I-50139 Florence, Italy. Phone: ++ 39-(0)55-5662434; Fax: ++ 39-(0)55-5662400. E-mail: l.filippi@meyer.it
(Received 12 February 2012; revised 21 March 2012; accepted 03 April 2012)
The Journal of Maternal-Fetal and Neonatal Medicine
2012
00
00
1
7
© 2012 Informa UK, Ltd.
10.3109/14767058.2012.683898
1476-7058
1476-4954
12February2012
21March2012
03April2012
Therapeutic hypothermia and prevention of skin complications
L. Filippi et al.
J M
at
er
n 
Fe
ta
l N
eo
na
ta
l M
ed
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Pr
of
es
so
r G
ia
n 
Ca
rlo
 D
i R
en
zo
 o
n 
06
/1
5/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
2  L. Filippi et al.
  The Journal of Maternal-Fetal and Neonatal Medicine
consisting of altered state of consciousness (irritability, lethargy, 
stupor, or coma) and ≥1 of the following signs: hypotonia, or 
abnormal reflexes including oculomotor or pupillary abnormalities, 
absent or weak sucking, or clinical seizures. Cooling was started 
within 6 h after birth and maintained for 72 h at 33.5 °C. Newborns 
older than 6 h of age at the time of evaluation and newborns with 
major congenital abnormalities or evidence of encephalopathy other 
than hypoxic–ischemic encephalopathy were excluded. Neonates 
treated with deep hypothermia were also excluded from this study. 
Outborn patients were initially cooled to around 35 °C of core 
body temperature at their birth hospital, by stopping the heating or 
applying ice bags near head and body during transfer to the NICU.
Upon arrival, newborns were cooled to 33.5 °C using a cooling 
blanket (Blanketrol® III, Hyper-hypothermia System; Cincinnati 
Sub-Zero, Cincinnati, OH), connected by a servomechanism to an 
esophageal probe. Newborns were lying on this cooling blanket 
that was covered by a thin sheet. Rectal temperature was continu-
ously monitored by a probe connected to a cardiomonitor (Infinity 
Delta; Dräger Medical System, Telford, PA) for simultaneous 
measurement of respiratory rate, heart rate, blood pressure, and 
oxygen saturation. Skin temperature was monitored with a skin 
probe on the abdominal wall by the radiant warmer thermal sensor 
or a temperature-monitoring unit (Mon-a-therm®; Mallinckrodt 
Medical, St Louis, MO). After 72 h of hypothermia, newborns 
were gradually rewarmed to 36.5–37 °C during the following 6–12 
h by increasing the automatic control set-point of 0.5 °C per hour. 
Newborns who complied with the entry criteria were enrolled 
until August 2009 in a pilot study for evaluating the safety of oral 
topiramate administration associated with hypothermia [14], and 
those admitted after February 2010 were enrolled in a random-
ized controlled study for evaluating the neuroprotective efficacy 
of combination treatment with topiramate and hypothermia [15].
Surface-cooling system
The cooling blanket unit used in our NICU can be set in manual 
control mode so that the operator can establish a priori the 
temperature of the circulating water, or in automatic mode, 
where the target temperature is reached with a servomechanism 
by heating or cooling the circulating water in relation to the 
newborn’s rectal or esophageal temperature.
From January to December 2008, patients were cooled using 
the cooling blanket in automatic mode, called “auto control mode” 
(ACM). With this type of mode the operator sets the patient’s target 
temperature (33.5 °C according to our protocol); if the patient’s actual 
temperature is lower than the target, the unit can heat the circulating 
water up to a maximum temperature of 42 °C (107.6 °F). Similarly, 
if the patient’s actual temperature is higher than the target, the unit 
can cool the circulating water down by a minimum of 4 °C (39.2 °F). 
With this operating mode, the newborn’s skin can be exposed to 
rapid and abrupt temperature changes. During this year two cases of 
SFN were observed.
Starting from January 2009 to December 2011, along with the 
application of the specific NP (see below) the cooling blanket 
was also used in another type of automatic mode, the so-called 
“gradient variable mode” (GVM) plus smart function. In this 
mode, after reaching the desired set-point temperature of 33.5 °C, 
the cooling blanket can be used to gradually control the patient’s 
temperature by maintaining the circulating water temperature at 
a specific pre-set gradient towards the patient’s body tempera-
ture. The objective was to expose the skin of newborns to slight 
temperature changes. In our unit a gradient of 5 °C was chosen: 
meaning that the water can only be heated to 38.5 °C (+5 °C) 
or cooled down to 28.5 °C (−5 °C). However, by activating the 
“smart” function, the water temperature gradient can be automat-
ically increased by 5 °C every 30 min until achieving the target.
NP
From January to December 2008, newborns treated with MH 
were managed according to a nonspecific NP, which provided 
only sporadic turning of newborns to prevent bedsores. Starting 
from January 2009, all cooled newborns were subjected to a 
specific NP. This included the mobilization of neonates with 
alternating pronation and supination every 3 h during cooling in 
order to avoid prolonged contact of a specific skin area with the 
cooling surface.
Study design
We retrospectively compared biochemical parameters and the 
incidence of adverse skin effects between the two groups of hypo-
thermic newborns treated with different cooling blanket modes 
and different NPs. The following blood tests were foreseen at T0 
(time zero, when cooling was initiated), T24, T48, T72, and 24 h after 
the rewarming process (T96) as planned in previous prospective 
studies [14,15]: blood gas analysis (corrected for body tempera-
ture), lactate, glucose, serum electrolyte level (sodium, potassium, 
chloride, calcium), liver (aspartate and alanine aminotransferase, 
total protein, coagulation tests) and renal function tests (blood 
urea nitrogen, creatinine), creatine-kinase, creatine-kinase MB 
isoenzyme, complete cell blood count, and C-reactive protein 
(CRP) level. These laboratory tests were planned.
Skin injuries were recorded via retrospective analyses of 
medical and nursing records of patients treated with hypo-
thermia, and with photographic documentation. Skin injuries 
were considered device-related when they were in contact with a 
cooling blanket, and not present at the time of hospital admission.
For newborns with SFN, a weekly or biweekly monitoring of 
total and ionized calcium levels was planned for at least 6 months 
or until the fat necrosis resolved.
Statistical analysis
The primary endpoint was the incidence of skin injury. The 
secondary endpoint was the different incidence of biochemical 
abnormalities between newborns treated with different nursing 
approaches. Differences in means between the cohorts were 
analyzed using the two-tailed Student’s t-test, with significance 
recognized at the P < 0.05 level.
The pilot study and the randomized controlled study regarding 
hypothermia [14,15] were approved by the local ethics commit-
tees. Written informed consent was obtained from both parents 
of all enrolled newborns. Consent to show the photographs of the 
two infants with SFN was obtained from their parents.
Results
During this period, thirty-six newborns admitted to our NICU 
for perinatal asphyxia met the admission criteria and were treated 
with whole-body hypothermia. All the newborns were cooled 
during transfer to the NICU, by stopping the heating; no one was 
cooled applying ice bags. Eleven newborns were treated using 
the ACM and twenty-eight neonates were cooled with the GVM 
plus the specific NP. Demographic data of these newborns are 
shown in Table I. Infant’s core temperatures were similar between 
the two groups during cooling (Figure 1a). Also mean blanket 
temperature was similar in both groups, but its fluctuation was 
significantly higher in the ACM group (Figure 1b).
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Within the group of newborns treated with the ACM mode, 
two neonates developed skin complications.
Patient 1
A full-term male infant born by urgent cesarean section for 
placental abruption started hypothermia at 5 h of age. About 20 
days after rewarming a nontender area of erythematous indurated 
plaques was observed on the lateral surface of the neck and back 
(Figure 2a). During the following days multiple indurated areas 
were palpable in the subcutaneous tissues of the trunk and arms. 
The skin over the indurated areas was bluish-purple. High levels 
of blood CRP (up to 15.2 mg/dl; normal value <0.5), not accom-
panied by a concurrent rising of procalcitonin, were observed. 
Platelet count and calcium level remained within the normal 
range during hospitalization and over the following weeks. 
Plasma CRP levels returned to normal range in about 40 days; 
skin recovery was complete, without scarring.
Patient 2
A full-term female infant born by instrumental vaginal delivery 
with application of vacuum extractor due to meconium-stained 
amniotic fluid, started hypothermia at 2 h of age. About 7 days 
after rewarming, multiple and confluent areas of bluish-purple 
indurated plaques were initially observed on the back (Figure 2b), 
and later extended to the posterior surface of thighs and armpits. 
The buttocks, protected by the diaper, were not affected. Blood 
CRP increased to 9.2 mg/dl, with normal levels of procalcitonin. 
Platelet count and calcium level were slightly reduced to 51·109/L 
after 72 h of hypothermia and 8.3 mg/dl after 48 h, respectively; 
both parameters normalized in a few days. Plasma CRP levels 
returned to normal range in about 20 days; skin recovery was 
complete, without scarring.
No newborns developed skin lesions in the group treated with 
the GVM plus smart function associated with the adopting of a NP.
The statistical analysis of the measured biochemical variables 
showed no significant differences between the two groups before 
beginning hypothermia (Table II). During cooling, some variables 
became statistically different. After 48 h of hypothermia in the 
group of newborns treated with ACM, the CRP levels remained 
significantly higher until after 24 h of rewarming, after 24 h of 
hypothermia, the platelet count remained significantly lower 
until after 24 h of rewarming, and after 72 h of hypothermia, 
the calcium levels remained significantly higher until after 24 h 
of rewarming (Figure 3). These differences remained even when 
the data of the two newborns with SFN were excluded from the 
ACM group.
Discussion
SFN of the newborn is a rare, inflammatory, transient and self-
limiting panniculitis typically present within the first few days or 
weeks of life with erythemato-violaceus, subcutaneous nodules 
or plaques, localized usually on the back, arms, buttocks, thighs 
or cheeks [16,17]. Although its pathogenesis is not fully known, 
it occurs almost exclusively in full-term or post-term neonates 
with normal size for dates or macrosomia. Most of these have 
an history of perinatal stress, local ischemia following trauma 
or pressure injury due to macrosomia and dystocic labor [17]. 
Maternal risk factors include gestational diabetes, preeclampsia, 
dyslipidemia, and maternal exposure to cocaine [18] or calcium 
antagonists [19] during pregnancy. However, other authors have 
recently suggested novel predisposing genetic risk factors, such as 
familial dyslipidemia or thrombophilia [16].
Table I. Demographic data of newborns treated with whole-body 
hypothermia.
Newborns 
treated with the 
ACM  
(n = 11)
Newborns treated 
with GVM plus 
specific NP  
(n = 28) P
Male, n (%) 6 (54.5) 19 (67.9) 0.449
Gestational age 
(weeks), mean ± SDa
39.4 ± 1.7 38.2 ± 2.8 0.235
Birth weight (g),  
mean ± SD
3,249 ± 656 3,102 ± 468 0.450
Cesarean section, n (%) 7 (63.6%) 16 (57.1%) 0.719
Stained amniotic fluid, 
n (%)
7 (63.6%) 12 (42.9%) 0.295
Outborn, n (%) 11 (100.0%) 28 (100.0%) N/A
Apgar score (1 min), 
mean ± SD
2.4 ± 2.1 2.0 ± 2.0 0.493
Apgar score (5 min), 
mean ± SD
3.9 ± 2.7 4.1 ± 2.2 0.803
Crib score, mean ± SD 4.4 ± 2.1 3.8 ± 2.0 0.493
Arterial pH,mean ± SD 6.90 ± 0.18 6.84 ± 0.16 0.310
Arterial BE, mean ± SD −19.5 ± 5.9 −22.5 ± 7.5 0.256
Arterial lactic acid 
(mmol/l), mean ± SD
15.0 ± 4.7 16.3 ± 4.5 0.526
Hour hypothermia 
beginning, mean ± SD
3.6 ± 1.2 3.6 ± 1.4 0.978
Subcutaneous fat 
necrosis, n (%)
2 (18.2) 0 (0.0) 0.014
ACM, auto control mode; BE, base excess; GVM, gradient variable mode; N/A, not 
applicable NP, nursing protocol.
aCalculated from maternal menstrual history, obstetrical data or by Ballard’s score.
Figure 1. Mean rectal and blanket temperature in both groups. (a)Mean rectal 
temperatures and (b) mean blanket temperature in newborns treated with 
ACM or GVM hypothermia during the 72-h intervention period. The vertical 
bars indicate SD. ACM, auto control mode; GVM, gradient variable mode.
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The high incidence of SFN in infants exposed to hypothermia 
has recently suggested that “cold stress” could play an important 
role in its pathogenesis [20]. SFN has been described in newborns 
following hypothermia when abandoned on the street [21] or 
exposed to cold weather [22]. Moreover, cases of SFN have been 
observed in newborns treated with applications of ice bags for 
supraventricular tachycardia [23–26], or subjected to whole-
body cooling before being placed on cardiopulmonary bypass for 
cardiovascular surgery [27–30]. Neonates have an increased risk 
of developing SFN due to the different composition of fatty acid 
concentrations. It has been postulated that the higher percentage 
of the saturated to unsaturated fats ratio in the brown fat of newborns 
compared to the adult yellow fat of older children has an increased 
tendency to crystallize with hypothermic injury. In fact, the melting 
point of palmitic acid (the main saturated fatty acid) is around 63 
°C, significantly higher than the melting point of the oleic acid (the 
main unsaturated fatty acid) (13 °C). This difference could explain 
why a small decrease in the temperature of newborns may result in 
solidification and crystallization of their fat [27,28,30].
More and more cases of SFN are currently being reported 
in infants treated with whole-body therapeutic hypothermia 
following perinatal asphyxia [6–13]. In infants cooled with ice 
bags and those treated with whole-body hypothermia using 
cooling blankets, skin lesions have been reported in areas 
subjected to contact with the surface of the cooling devices, as 
observed in both of our patients. Skin lesions have been reported 
in ~20% of adult patients cooled with surface-cooling devices, 
even though only 6% were device-related [31]. These injuries were 
also more frequent in patients in shock-requiring vasopressors, 
or with a poor left ventricular ejection fraction, suggesting that 
cutaneous blood flow may play an important role [31]. In short, 
general ischemia after perinatal asphyxia and local ischemia after 
dystocic labor are both likely to play a key role in the development 
of SFN; however, skin-surface-cooling, inducing cutaneous and 
visceral vasoconstriction [32], may also lead to local ischemia and 
hypoxemia, thus causing the onset of SFN.
We hypothesized that wide and rapid changes of circulating 
water from cold to hot in cooling blanket, as observed mainly in 
newborns cooled with ACM hypothermia (Figure 1b), together 
with persistent pressure on the same skin regions, may compro-
mise local perfusion, leading to local hypoxemia and subsequently 
putting these infants at risk of skin lesions. For these reasons we 
investigated the efficacy of our strategy, focusing on periodic 
mobilization and a gentler cooling blanket setting, in order to 
avoid abrupt temperature changes. Our experience is therefore 
very encouraging considering that after adopting this combined 
protocol the incidence of SFN was nil.
Nevertheless, this study has important limitations. First, the 
sample sizes are too small to draw statistically significant conclu-
sions. This means that this study can only provide suggestions and 
recommendations for broader studies. Second, the patients studied 
had clinical features consistent with SFN, but they did not undergo 
biopsies or histological examinations necessary for differential diag-
nosis of cold panniculitis [23]. In fact, although both diseases may be 
clinically indistinguishable [24], their histopathologic findings are 
different [20]. This means that we can only draw the general conclu-
sion that our protocol reduces the risk of skin damage. Third, the 
simultaneous introduction of a NP and a new cooling mode makes 
it difficult to determine which was the most effective procedure.
Even though SFN is usually a self-limiting disease that resolves 
within a few weeks or months without scarring, at times rare 
systemic complications including anemia, thrombocytopenia, 
hypoglycemia, hypertriglyceridemia, and hypercalcemia may 
occur [33]. Hypercalcemia, which has been reported to develop 
in approximately one-third of newborns with SFN [17] but also in 
over 50% [16] is a very serious complication because it can also be 
fatal. It usually occurs between 2 and 16 weeks, when SFN begins 
to resolve and may either be asymptomatic or manifest with failure 
to thrive, lethargy, irritability, hypotonia, vomiting and, in severe 
cases, calcification of the soft tissues. Nephrolithiasis, nephrocal-
cinosis, renal failure, metastatic calcification in the pericardium 
and brain, and also cardiac arrest have been described [34–36]. 
Some authors reported an association with elevated prostaglandin 
levels that can lead to osteoclast activation and calcium release 
from granulomas or necrotic fat [37]. For others, hypercalcemia 
Figure 2. Subcutaneous fat necrosis. Erythematous and indurated plaques on 
the back of (a) patient 1 and (b) patient 2 after direct contact with the cooling 
blanket.
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Table II. Blood parameters in infants cooled with auto control mode (ACM) or gradient variable mode (GVM) plus specific nursing protocol (NP).
Pre 24 h 48 h 72 h
24-h 
post-rewarming
pH (−log[H+]) ACM 7.242 ± 0.07 7.338 ± 0.07 7.330 ± 0.05 7.362 ± 0.09 7.391 ± 0.07
GVM + NP 7.209 ± 0.11 7.321 ± 0.06 7.328 ± 0.06 7.322 ± 0.09 7.383 ± 0.05
PCO2 (mm Hg) ACM 38.0 ± 12.2 45.7 ± 10.1 48.3 ± 8.4 44.5 ± 9.4 42.3 ± 6.1
GVM + NP 35.2 ± 15.2 43.2 ± 7.4 45.4 ± 9.9 47.8 ± 12.5 43.1 ± 8.0
PO2 (mm Hg) ACM 62.5 ± 26.7 70.6 ± 32 69.4 ± 19.3 91.7 ± 22.6 82.3 ± 24.2
GVM + NP 80.1 ± 27.3 79.5 ± 22.1 73.6 ± 29.9 78.0 ± 31.2 72.5 ± 19.2
BE (mmol/l) ACM −10.7 ± 3.2 −1.5 ± 3.0 −0.5 ± 3.9 −0.4 ± 4.3 0.8 ± 4.4
GVM + NP -12.6 ± 5.4 −4.1 ± 3.8 −2.8 ± 3.2 −2.1 ± 3.9 0.1 ± 3.6
HCO3 (mmol/l) ACM 16.0 ± 2.4 22.5 ± 2.7 23.4 ± 3.0 24.0 ± 3.7 25.0 ± 3.7
GVM + NP 15.5 ± 4.1 21.7 ± 2.3 22.6 ± 2.8 22.8 ± 2.7 24.3 ± 3.2
Lactate (mmol/l) ACM 9.5 ± 5.3 4.1 ± 2.2 2.6 ± 1.3 2.0 ± 1.5 1.8 ± 0.8
GVM + NP 10.7 ± 6.5 4.0 ± 3.3 3.0 ± 3.3 1.9 ± 1.4 1.7 ± 1.0
Glucose (mg/dl) ACM 108 ± 41 83 ± 23 72 ± 14 68 ± 16 79 ± 18
GVM + NP 118 ± 59 92 ± 28 81 ± 21 82 ± 21 90 ± 17
Na (mmol/l) ACM 135 ± 3.0 134 ± 4.3 134 ± 4.8 136 ± 3.5 136 ± 4.7
GVM + NP 135 ± 5.0 133 ± 4.7 132 ± 5.1 134 ± 4.6 137 ± 5.1
K (mmol/l) ACM 4.3 ± 0.8 4.2 ± 0.5 4.1 ± 0.7 3.8 ± 0.6 3.7 ± 0.7
GVM + NP 4.0 ± 0.5 4.2 ± 0.7 4.3 ± 0.9 4.1 ± 0.8 3.7 ± 0.6
Ca (mg/dl) ACM 9.0 ± 1.3 8.8 ± 0.7 8.7 ± 0.7 9.6 ± 0.8* 9.5 ± 0.7*
GVM + NP 8.7 ± 0.4 8.7 ± 0.7 8.7 ± 0.7 8.7 ± 0.8* 8.6 ± 0.9*
Creatinine (mg/dl) ACM 0.98 ± 0.2 0.95 ± 0.3 0.90 ± 0.5 0.85 ± 0.5 0.95 ± 0.7
GVM + NP 1.27 ± 0.4 1.17 ± 0.4 0.86 ± 0.4 0.76 ± 0.3 0.80 ± 0.3
Urea nitrogen (mg/dl) ACM 24.1 ± 6.9 27.8 ± 9.7 27.6 ± 16.8 31.1 ± 20.7 30.2 ± 18.1
GVM + NP 27.7 ± 11.2 35.8 ± 12.9 37.4 ± 17.2 34.6 ± 17.9 32.3 ± 15.5
Aspartate aminotransferase (U/l) ACM 140 ± 78 326 ± 282 133 ± 73 146 ± 81 70 ± 41
GVM + NP 163 ± 110 153 ± 148 101 ± 42 76 ± 35 57 ± 27
Alanine aminotransferase (U/l) ACM 77 ± 45 121 ± 57 61 ± 36 87 ± 21 45 ± 17
GVM + NP 86 ± 52 101 ± 68 71 ± 49 75 ± 35 51 ± 32
Total protein (g/dl) ACM 5.3 ± 1.3 4.8 ± 0.8 4.9 ± 0.7 5.1 ± 0.8 5.2 ± 0.7
GVM + NP 5.7 ± 0.5 5.2 ± 0.7 5.2 ± 0.6 5.0 ± 0.5 5.2 ± 0.6
Creatine-kinase (U/l) ACM 1,488 ± 839 2,324 ± 1,497 1,286 ± 997 1,588 ± 590 326 ± 150
GVM + NP 1,879 ± 581 1,667 ± 978 1,601 ± 1,016 1,575 ± 787 481 ± 321
Creatine-kinase MB (U/l) ACM 84 ± 62 69 ± 42 74 ± 54 74 ± 41 63 ± 38
GVM + NP 69 ± 42 108 ± 49 104 ± 80 71 ± 41 63 ± 34
Hemoglobin (g/dl) ACM 15.1 ± 5.5 15.7 ± 3.4 14.9 ± 3.0 14.8 ± 3.2 13.3 ± 2.6
GVM + NP 16.3 ± 2.3 15.6 ± 2.8 14.8 ± 2.6 13.7 ± 2.5 12.1 ± 2.6
White blood cell count (109/l) ACM 20.9 ± 10.5 11.9 ± 4.4 9.5 ± 3.9 7.9 ± 3.8 8.2 ± 1.9
GVM + NP 21.9 ± 7.8 14.5 ± 4.7 11.9 ± 3.8 8.8 ± 2.3 10.4 ± 3.4
Platelet count (109/l) ACM 195 ± 75 154 ± 60* 134 ± 61* 116 ± 69* 118 ± 69*
GVM + NP 255 ± 99 232 ± 82* 210 ± 78* 210 ± 73* 261 ± 98*
C-reactive protein (mg/l) ACM 1.3 ± 2.7 3.2 ± 2.0 5.3 ± 3.8 * 5.9 ± 4.4* 5.8 ± 4.0*
GVM + NP 0.6 ± 1.5 1.4 ± 1.8 2.3 ± 2.1* 3.3 ± 2.3* 3.3 ± 3.0*
Prothrombin time INR ACM 1.83 ± 0.5 1.86 ± 0.5 1.74 ± 0.5 1.46 ± 0.4 1.25 ± 0.2
GVM + NP 2.11 ± 0.7 1.75 ± 0.5 1.59 ± 0.8 1.30 ± 0.3 1.18 ± 0.3
Activated partial thromboplastin 
time ratio
ACM 2.02 ± 1.0 1.98 ± 0.6 1.98 ± 0.6 1.92 ± 0.6 1.63 ± 0.3
GVM + NP 1.81 ± 0.5 1.65 ± 0.4 1.73 ± 0.7 1.59 ± 0.6 1.38 ± 0.4
Fibrinogen (mg/dl) ACM 219 ± 72 342 ± 117 368 ± 161 443 ± 153 490 ± 220
GVM + NP 234 ± 76 279 ± 87 319 ± 106 350 ± 117 415 ± 117
D-dimers (ng/ml) ACM 2,238 ± 928 1,069 ± 874 384 ± 279 288 ± 208 423 ± 391
GVM + NP 2,402 ± 510 649 ± 478 696 ± 531 729 ± 690 228 ± 213
Mean ± SD.
AVM, auto control mode; GVM, gradient variable mode; INR, international normalized ratio; NP, nursing protocol.
*P < 0.05.
INR means International normalized ratio; BE means Base excess; MB is the name of the isoenzyme and it does not have to be expanded.
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is believed to be caused by an excessive extra renal production 
of 1,25-dihydroxyvitamin D [17,33,34,36,38] by the granuloma-
tous macrophages, as observed in other granulomatous inflam-
mations, such as sarcoidosis [39] which increases the intestinal 
calcium uptake [20].
These complications were not detected in our patients. 
However, the comparison of values of C protein and calcemia 
showed significantly higher values in the group of newborns 
treated with the ACM mode and the platelet count was signifi-
cantly lower in this group. We cannot exclude a bias due to the 
small sample size; however, such data could suggest a more 
pronounced skin inflammation in the group of newborns exposed 
to abrupt changes of temperature, even if SFN was only observed 
in two neonates. This suggestion is supported by the observation 
that these differences continued between the two groups even 
after the exclusion of the two infants with SFN.
In conclusion, the lower incidence of skin injuries and lower 
CRP and serum calcium levels in newborns treated with the GVM 
mode increases the suspicion that rapid changes in temperature 
may be harmful to infants. Further studies are recommended to 
confirm the benefits of hypothermia obtained in a more gentle 
mode associated with a NP with periodic mobilization.
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